Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa
Links shared publicly online about this topic.
- 234total visits
Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa
Somaxon Pharmaceuticals, Inc. and Paladin Labs Inc. today announced that they have entered into an exclusive collaboration under which Paladin will commercialize Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance in Canada, South America and Africa.
View full resource at news-medical.net
Tags: Sleep Disorder, Sleep, Insomnia, Pharma
Most Recently Shared on June 8, 2011 at 2:24 pm By:
Paladin to commercialize Silenor for treatment of insomnia in Canada, South America and Africa: Somaxon Pharmace... http://bit.ly/iseLpT
Advertisement
